Vulnerability Description
An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capture of user login information.
CVSS Score
9.8
CRITICAL
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H
Affected Products
| Vendor | Product | Versions |
|---|---|---|
| Fresenius-Kabi | Pharmahelp Firmware | 5.1.759.0 |
| Fresenius-Kabi | Pharmahelp | - |
Related Weaknesses (CWE)
References
- https://www.fresenius-kabi.com/de-at/produkte/pharmahelp-compounderProduct
- https://www.fresenius.com/sites/default/files/2023-11/Fresenius%20-%20CVE-2022-4
- https://www.fresenius.com/sites/default/files/2023-12/Fresenius%20-%20CVE-2022-4
- https://www.fresenius-kabi.com/de-at/produkte/pharmahelp-compounderProduct
- https://www.fresenius.com/sites/default/files/2023-11/Fresenius%20-%20CVE-2022-4
- https://www.fresenius.com/sites/default/files/2023-12/Fresenius%20-%20CVE-2022-4
FAQ
What is CVE-2022-45611?
CVE-2022-45611 is a vulnerability with a CVSS score of 9.8 (CRITICAL). An issue was discovered in Fresenius Kabi PharmaHelp 5.1.759.0 allows attackers to gain escalated privileges via via capture of user login information.
How severe is CVE-2022-45611?
CVE-2022-45611 has been rated CRITICAL with a CVSS base score of 9.8/10. This is considered a critical vulnerability requiring immediate attention.
Is there a patch for CVE-2022-45611?
Check the references section above for vendor advisories and patch information. Affected products include: Fresenius-Kabi Pharmahelp Firmware, Fresenius-Kabi Pharmahelp.